By Michael Dabaie

Bristol Myers Squibb said a Phase 3 study of Breyanzi as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma met its primary and key secondary objectives.

Bristol Myers said the study looked at Breyanzi compared to salvage therapy followed by high-dose chemotherapy and stem cell transplant, currently considered a gold-standard treatment for these patients.

The company said an interim analysis by an independent review committee showed the study met its primary endpoint of demonstrating a clinically meaningful and highly statistically significant improvement in event-free survival. The trial also met key secondary endpoints of complete response rate and progression-free survival compared to standard of care.

Overall survival data were immature at the time of the interim analysis, Bristol Myers said.

The results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell transplant in relapsed or refractory large B-cell lymphoma, and support the potential of Breyanzi in earlier lines of therapy in this population, Bristol Myers said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

06-10-21 0743ET